Act Two Investors LLC Invests $30.67 Million in IQVIA Holdings Inc. $IQV

Key Points

• Act Two Investors LLC initiated a $30.67 million position in IQVIA, purchasing 158,746 shares and making the stock its fifth-largest holding. Institutional investors collectively own 89.62% of IQVIA.
• IQVIA exceeded quarterly expectations with adjusted EPS of $3.15 versus the $3.03 consensus and revenue of $4.37 billion, up 8.7% year over year. The company also authorized a $2 billion share buyback.
• Analysts maintain a generally positive view, with a “Moderate Buy” consensus and an average price target of $241.88. However, insiders sold 12,913 shares worth about $3.10 million over the past three months.

Act Two Investors LLC purchased a new position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 158,746 shares of the medical research company's stock, valued at approximately $30,673,000. IQVIA accounts for about 6.2% of Act Two Investors LLC's holdings, making the stock its 5th largest holding. Act Two Investors LLC owned 0.10% of IQVIA as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. BlackRock Inc. bought a new position in shares of IQVIA during the second quarter valued at approximately $2,811,292,000. Boston Partners bought a new position in IQVIA in the third quarter worth approximately $676,698,000. Norges Bank purchased a new stake in IQVIA during the fourth quarter worth $497,445,000. Victory Capital Management Inc. boosted its position in IQVIA by 2,628.1% during the 4th quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company's stock valued at $377,670,000 after acquiring an additional 1,614,063 shares in the last quarter. Finally, Orbis Allan Gray Ltd increased its holdings in shares of IQVIA by 96.5% in the 4th quarter. Orbis Allan Gray Ltd now owns 1,901,091 shares of the medical research company's stock valued at $428,525,000 after acquiring an additional 933,554 shares during the period. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other IQVIA news, insider W Richard Staub sold 5,500 shares of the company's stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $232.68, for a total value of $1,279,740.00. Following the completion of the transaction, the insider owned 13,312 shares in the company, valued at approximately $3,097,436.16. This represents a 29.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Eric Sherbet sold 5,000 shares of the stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the sale, the insider directly owned 20,999 shares in the company, valued at approximately $5,232,110.84. The trade was a 19.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 12,913 shares of company stock worth $3,098,793 over the last three months. Corporate insiders own 1.70% of the company's stock.

IQVIA Stock Down 0.4%

NYSE:IQV opened at $240.25 on Wednesday. The company's fifty day moving average price is $208.88 and its 200-day moving average price is $186.72. The firm has a market capitalization of $39.54 billion, a P/E ratio of 29.81, a PEG ratio of 2.01 and a beta of 1.18. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $251.36. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.03 by $0.12. The business had revenue of $4.37 billion during the quarter, compared to analysts' expectations of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The company's revenue for the quarter was up 8.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, equities research analysts anticipate that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA announced that its board has approved a share repurchase program on Thursday, May 7th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares buyback programs are usually a sign that the company's leadership believes its shares are undervalued.

Analyst Ratings Changes

Several research analysts have recently commented on the company. BMO Capital Markets boosted their price target on IQVIA from $210.00 to $270.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 29th. Deutsche Bank Aktiengesellschaft set a $240.00 target price on shares of IQVIA in a report on Thursday, July 9th. Mizuho raised their target price on shares of IQVIA from $215.00 to $230.00 and gave the company an "outperform" rating in a research note on Monday, July 13th. William Blair raised IQVIA to a "strong-buy" rating in a research report on Tuesday, July 28th. Finally, Weiss Ratings upgraded IQVIA from a "hold (c-)" rating to a "hold (c)" rating in a research note on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, IQVIA currently has a consensus rating of "Moderate Buy" and an average price target of $241.88.

About IQVIA

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source